Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ROCKVILLE, MD, Jan. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
-
32.7% Objective response rate in HER2+ IHC 3+ second-line gastric cancer patientsWell tolerated in dose escalation and expansion cohorts ROCKVILLE, MD, Jan. 17, 2019 (GLOBE NEWSWIRE) -- ...
-
Rockville, MD, Jan. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
-
ROCKVILLE, MD, Dec. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
-
Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patientsTranslational studies suggest potential strategy for biomarker-based patient selection ...
-
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing developmentExpand Zai Lab’s late-stage clinical pipeline with margetuximab and obtain rights to...
-
ROCKVILLE, MD, Nov. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
-
ROCKVILLE, MD, Nov. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
-
Enoblituzumab + pembrolizumab combination study data reported: ORRs in anti-PD-1/PD-L1 naïve SCCHN and NSCLC cohorts benchmarked favorably vs. approved anti-PD-1 agentsInterim data from Phase 1 dose...
-
Margetuximab: Phase 3 SOPHIA study enrollment completed; topline results 1Q 2019PD-1 franchise: MGD013 cohort expansions initiated; $15 million in MGA012 milestones triggered; MGD019 IND clearedB7-H3...